Secreted phosphoprotein 24 kD inhibits growth of human prostate cancer cells stimulated by BMP-2

Anticancer Research

Volumn 36, Issue 11, 2016, Pages 5773-5780

  Lao, Lifeng ^a   Shen, Jia ^b   Tian, Haijun ^b   Yao, Qingqiang ^b   Li, Yawei ^b   Qian, Lie ^a   Murray, Samuel S ^b,c   Wang, Jeffrey C ^d  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Bone metastasis; Bone morphogenetic protein 2; Prostate cancer; Secreted phosphoprotein 24 kD

Indexed keywords

ANTINEOPLASTIC AGENT; BONE MORPHOGENETIC PROTEIN 2; CYCLINE; PHOSPHOPROTEIN; SECRETED PHOSPHOPROTEIN 24; UNCLASSIFIED DRUG; BMP2 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL PROLIFERATION; CELL STIMULATION; CELL VIABILITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; MTT ASSAY; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CANCER CELL LINE; RADIOGRAPHY; TUMOR GROWTH; TUMOR MODEL; TUMOR VOLUME; TUMOR XENOGRAFT; TUNEL ASSAY; PATHOLOGY; PHYSIOLOGY; PROSTATE TUMOR; TUMOR CELL LINE;

BONE MORPHOGENETIC PROTEIN 2; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; MALE; PHOSPHOPROTEINS; PROSTATIC NEOPLASMS;

EID: 84993964790     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: 10.21873/anticanres.11161     Document Type: Article

References (30)

1. Siegel RL, Miller KD and Jemal A: Cancer statistics, 2015. CA Cancer J Clin 65(1): 5-29, 2015.
2. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin 63(1): 11-30, 2013.
3. Gundem G, Van Loo P, Kremeyer B, Alexandrov LB, Tubio JM, Papaemmanuil E, Brewer DS, Kallio HM, Hognas G, Annala M, Kivinummi K, Goody V, Latimer C, O'Meara S, Dawson KJ, Isaacs W, Emmert-Buck MR, Nykter M, Foster C, Kote-Jarai Z, Easton D, Whitaker HC, Neal DE, Cooper CS, Eeles RA, Visakorpi T, Campbell PJ, McDermott U, Wedge DC and Bova GS: The evolutionary history of lethal metastatic prostate cancer. Nature 520(7547): 353-357, 2015.
4. Merglen A, Schmidlin F, Fioretta G, Verkooijen HM, Rapiti E, Zanetti R, Miralbell R and Bouchardy C: Short- and long-term mortality with localized prostate cancer. Arch Intern Med 167(18): 1944-1950, 2007.
5. Gundala SR, Yang C, Lakshminarayana N, Asif G, Gupta MV, Shamsi S and Aneja R: Polar biophenolics in sweet potato greens extract synergize to inhibit prostate cancer cell proliferation and in vivo tumor growth. Carcinogenesis 34(9): 2039-2049, 2013.
6. Li K, Dias SJ, Rimando AM, Dhar S, Mizuno CS, Penman AD, Lewin JR and Levenson AS: Pterostilbene acts through metastasis-associated protein 1 to inhibit tumor growth, progression and metastasis in prostate cancer. PLoS One 8(3): e57542, 2013.
7. Rick FG, Schally AV, Szalontay L, Block NL, Szepeshazi K, Nadji M, Zarandi M, Hohla F, Buchholz S and Seitz S: Antagonists of growth hormone-releasing hormone inhibit growth of androgen-independent prostate cancer through inactivation of ERK and Akt kinases. Proc Natl Acad Sci USA 109(5): 1655-1660, 2012.
8. Tanaka H, Kono E, Tran CP, Miyazaki H, Yamashiro J, Shimomura T, Fazli L, Wada R, Huang J, Vessella RL, An J, Horvath S, Gleave M, Rettig MB, Wainberg ZA and Reiter RE: Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance. Nat Med 16(12): 1414-1420, 2010.
9. Hsu YH, Wu CY, Hsing CH, Lai WT, Wu LW and Chang MS: Anti-IL-20 Monoclonal Antibody Suppresses Prostate Cancer Growth and Bone Osteolysis in Murine Models. PLoS One 10(10): e139871, 2015.
10. Jin M, Zhang T, Liu C, Badeaux MA, Liu B, Liu R, Jeter C, Chen X, Vlassov AV and Tang DG: miRNA-128 suppresses prostate cancer by inhibiting BMI-1 to inhibit tumor-initiating cells. Cancer Res 74(15): 4183-4195, 2014.
11. Zhao X, Wang Y, Deng R, Zhang H, Dou J, Yuan H, Hou G, Du Y, Chen Q and Yu J: miR186 suppresses prostate cancer progression by targeting Twist1. Oncotarget doi: doi: 10.18632/oncotarget.8887, 2016.
12. Bleuming SA, He XC, Kodach LL, Hardwick JC, Koopman FA, Ten KF, van Deventer SJ, Hommes DW, Peppelenbosch MP, Offerhaus GJ, Li L and van den Brink GR: Bone morphogenetic protein signaling suppresses tumorigenesis at gastric epithelial transition zones in mice. Cancer Res 67(17): 8149-8155, 2007.
13. Thawani JP, Wang AC, Than KD, Lin CY, La Marca F and Park P: Bone morphogenetic proteins and cancer: review of the literature. Neurosurgery 66(2): 233-246, 246, 2010.
14. Langenfeld EM, Kong Y and Langenfeld J: Bone morphogenetic protein 2 stimulation of tumor growth involves the activation of Smad-1/5. Oncogene 25(5): 685-692, 2006.
15. Kokorina NA, Zakharkin SO, Krebsbach PH and Nussenbaum B: Treatment effects of rhBMP-2 on invasiveness of oral carcinoma cell lines. Laryngoscope 121(9): 1876-1880, 2011.
16. Kang MH, Oh SC, Lee HJ, Kang HN, Kim JL, Kim JS and Yoo YA: Metastatic function of BMP-2 in gastric cancer cells: the role of PI3K/AKT, MAPK, the NF-kappaB pathway, and MMP-9 expression. Exp Cell Res 317(12): 1746-1762, 2011.
17. Dai J, Keller J, Zhang J, Lu Y, Yao Z and Keller ET: Bone morphogenetic protein-6 promotes osteoblastic prostate cancer bone metastases through a dual mechanism. Cancer Res 65(18): 8274-8285, 2005.
18. Ide H, Yoshida T, Matsumoto N, Aoki K, Osada Y, Sugimura T and Terada M: Growth regulation of human prostate cancer cells by bone morphogenetic protein-2. Cancer Res 57(22): 5022-5027, 1997.
19. Feeley BT, Krenek L, Liu N, Hsu WK, Gamradt SC, Schwarz EM, Huard J and Lieberman JR: Overexpression of noggin inhibits BMP-mediated growth of osteolytic prostate cancer lesions. Bone 38(2): 154-166, 2006.
20. Tian H, Bi X, Li CS, Zhao KW, Brochmann EJ, Montgomery SR, Aghdasi B, Chen D, Daubs MD, Wang JC and Murray SS: Secreted phosphoprotein 24 kD (Spp24) and Spp14 affect TGF-beta induced bone formation differently. PLoS One 8(8): e72645, 2013.
21. Tian H, Li CS, Zhao KW, Wang JC, Duarte ME, David CL, Phan K, Atti E, Brochmann EJ and Murray SS: A carboxy terminal BMP/TGF-beta binding site in secreted phosphoprotein 24 kD independently affects BMP-2 activity. J Cell Biochem 116(4): 667-676, 2015.
22. Li CS, Tian H, Zou M, Zhao KW, Li Y, Lao L, Brochmann EJ, Duarte ME, Daubs MD, Zhou YH, Murray SS and Wang JC: Secreted phosphoprotein 24 kD (Spp24) inhibits growth of human pancreatic cancer cells caused by BMP-2. Biochem Biophys Res Commun 466(2): 167-172, 2015.
23. Lee KB, Murray SS, Duarte ME, Spitz JF, Johnson JS, Song KJ, Brochmann EJ, Taghavi CE, Keorochana G, Liao JC and Wang JC. Effects of the bone morphogenetic protein binding protein spp24 (secreted phosphoprotein 24 kD) on the growth of human lung cancer cells. J Orthop Res 29(11): 1712-1718, 2011.
24. Kwon H, Kim HJ, Rice WL, Subramanian B, Park SH, Georgakoudi I and Kaplan DL: Development of an in vitro model to study the impact of BMP-2 on metastasis to bone. J Tissue Eng Regen Med 4(8): 590-599, 2010.
25. Murray EJ, Murray SS, Simon R and Behnam K: Recombinant expression, isolation, and proteolysis of extracellular matrix-secreted phosphoprotein-24 kDa. Connect Tissue Res 48(6): 292-299, 2007.
26. Masuda H, Fukabori Y, Nakano K, Takezawa Y, CSuzuki T and Yamanaka H: Increased expression of bone morphogenetic protein-7 in bone metastatic prostate cancer. Prostate 54(4): 268-274, 2003.
27. Feeley BT, Gamradt SC, Hsu WK, Liu N, Krenek L, Robbins P, Huard J and Lieberman JR: Influence of BMPs on the formation of osteoblastic lesions in metastatic prostate cancer. J Bone Miner Res 20(12): 2189-2199, 2005.
28. Brochmann EJ, Simon RJ, Jawien J, Behnam K, Sintuu C, Wang JC and Murray SS: Carboxy terminus of secreted phosphoprotein-24 kDa (spp24) is essential for full inhibition of BMP-2 activity. J Orthop Res 28(9): 1200-1207, 2010.
29. Sintuu C, Murray SS, Behnam K, Simon R, Jawien J, Silva JD, Duarte ME and Brochmann EJ: Full-length bovine spp24 [spp24 (24-203)] inhibits BMP-2 induced bone formation. J Orthop Res 26(6): 753-758, 2008.
30. Lai TH, Fong YC, Fu WM, Yang RS and Tang CH: Osteoblasts-derived BMP-2 enhances the motility of prostate cancer cells via activation of integrins. Prostate 68(12): 1341-1353, 2008.